

From: Morris, Nevitt  
To: Jim.wang@sparktx.com  
Cc: Morris, Nevitt  
Subject: BLA 125610 Information Request re: AC question 10.04.17  
Date: Thursday, October 05, 2017 10:06:44 AM  
Attachments: image001.png  
Importance: High

(File Attachment comment)  
Hi Jim:

The clinical team had the following Information Request (highlighted in Yellow) that needed clarification at your earliest convenience:

Please clarify the following regarding the size of the navigation course:

In your AC briefing document, the mobility course is described as each measuring 5' x 10' (Page 50 of 149)  
In your Summary of Clinical Efficacy (Module 2.7.3), the MT course was described as 7' x 12' (with one-foot border, Page 68).

Which size should be used in the AC presentation?

Thanks,

Nevitt

Nevitt Morris

Nevitt  
Morris,  
RN,  
BSN,  
BS  
Consumer  
Safety  
Officer  
Office  
of  
Tissues  
and  
Advanced  
Therapies

Center  
for  
Biologics  
Evaluation  
and  
Research  
(CBER)

U.S.  
Food  
and  
Drug  
Administration  
Building  
71,  
Room  
4207  
10903  
New  
Hampshire  
Avenue  
Silver  
Spring,  
MD 20993  
Phone: (240)  
402-8269  
Fax: (301)  
595-1303

[Nevitt.Morris@fda.hhs.gov](mailto:Nevitt.Morris@fda.hhs.gov)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS  
ADDRESSED  
AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND  
PROTECTED  
FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person  
authorized to deliver  
(Unsigned signature field (Click to sign)) Signature field is unsigned

the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

